Scale icon

Impact of Obesity

Obesity Is a Prevalent and Costly Disease1

Obesity has a significant clinical and economic impact because it can be the underlying cause of many comorbidities, such as type 2 diabetes and heart disease.1

Obesity is a chronic disease, not merely a lifestyle issue2

Why is it so hard to lose weight and why does it return? As shown here, there are multiple factors
that may affect weight loss and weight maintenance.

Brain icon

Science of Obesity

When weight is lost, the body
increases the hunger hormone and
decreases the fullness hormone3

DNA helix icon


Certain genes may play an important role
in how much weight is gained4,5

Bed icon


Not enough sleep and lack
of physical activity may be
contributing factors6

Broccoli icon


Eating healthy may be challenging
(eg, location, price, time to prepare).
Some individuals have no place to

All of this information and more in an easy-to-read learning module



The Science of Obesity Video

Would you like to learn more about the science of obesity? This video provides a basic scientific understanding of obesity, its potential causes, and potential treatments.

Additional Resources

Learn More
Learn More

50 State Obesity Fact Sheets

Up-to-date information about risks, implications, and productivity data for your state.


Obesity Conventions Handout

Learn to navigate weight-management and AOM coverage in your organization.

Explore the Next Topic

Contact us to learn more

Find an Account Manager

References: 1. Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203. 2. Recognition of Obesity as a Disease H-440.842. American Medical Association. Accessed May 18, 2023. 3. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. 4. Hebebrand J, Hinney A, Knoll N, Volckmar AL, Scherag A. Molecular genetic aspects of weight regulation. Dtsch Arztebl Int. 2013;110(19):338-344. 5. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723. 6. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: an Endocrine Society Scientific Statement. Endocr Rev. 2017;38(4):267-296.


Now Exiting

You are about to leave the website of Novo Nordisk Works.


Are You a Formulary Decision Maker?

The information on the following page is intended for Formulary Decision Makers only. Formulary Decision Makers are public and private sector payers, formulary committee members, or people in similar positions with expertise in healthcare economic analysis and who are involved in deciding drug coverage or reimbursement eligibility.

Sorry, you are not authorized to access this content

The role you selected is not considered a formulary decision maker.